摘要
Farnesoid X receptor (FXR) was considered as a promising drug target in the treatment of cholestasis, druginduced liver injury, and non-alcoholic steatohepatitis (NASH). However, the existing FXR agonists have shown different degrees of side effects in clinical trials without clear interpretation. MET-409 in clinical phase III, has been proven significantly fewer side effects than that of other FXR agonists. This may be due to the completely different structure of FEX and other non-steroidal FXR agonists. Herein, the structure-based drug design was carried out based on FEX, and the more active FXR agonist LH10 (FEX EC50 = 0,3 mu M; LH10 EC50 = 0.14 mu M)) was screened out by the comprehensive SAR studies. Furthermore, LH10 exhibited robust hepatoprotective activity on the ANIT-induced cholestatic model and APAP-induced acute liver injury model, which was even better than positive control OCA. In the nonalcoholic steatohepatitis (NASH) model, LH10 significantly improved the pathological characteristics of NASH by regulating several major pathways including lipid metabolism, inflammation, oxidative stress, and fibrosis. With the above attractive results, LH10 is worthy of further evaluation as a novel agent for the treatment of liver disorders.
学科与关键词
- Discovery of a tricyclic farnesoid X receptor agonist HEC96719, a clinical candidate for treatment of non-alcoholic steatohepatitisCao, Shengtian; Yang, Xinye; Zhang, Zheng; Wu, Junwen; Chi, Bo; Chen, Hong; Yu, Jianghong; Feng, Shanshan; Xu, Yulin; Li, Jing; Zhang, Yingjun; Wang, Xiaojun*; Wang, Yan*European Journal of Medicinal Chemistry, 2022, 230: 114089.被引 9
- Design, synthesis, and biological studies of novel sulfonamide derivatives as farnesoid X receptor agonistsWang, Wenxin; Cao, Zhijun; Yang, Zhongcheng; Chen, Ya; Yao, Huixin; Zhou, Danting; Ou, Peixin; Huang, Wanqiu; Jiao, Shixuan; Chen, Siliang; Chen, Lianru; Liu, Yuxia; Mao, Jianming; Xie, Jiayi; Xiang, Ruojing; Yang, Yuanqian; Chen, Yisi; Yang, Yonghong; Tan, Liyun; Tang, Haolong; Zhang, Luyong*; Li, Zheng*European Journal of Medicinal Chemistry, 2023, 258: 115614.
- Discovery of a novel and orally active Farnesoid X receptor agonist for the protection of acetaminophen-induced hepatotoxicityCai, Zongyu; Wang, Bin; Zhou, Zongtao; Zhao, Xin; Hu, Lijun; Ren, Qiang; Deng, Liming; Li, Zheng*; Wang, Guangji*Chemical Biology and Drug Design, 2022, 99(3): 483-495.被引 3
